AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago ts2.tech. Such dramatic swings are not unusual for a pre-revenue biotech stock – especially one at the intersection of two hot themes that can amplify volatility.